MedTrace Logo

Pharmacokinetic Study of AEB071 in Patients Following Liver Transplantation

NCT00545259 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2020-12-08

No results posted yet for this study

Summary

The study will evaluate the pharmacokinetic profile of AEB071 in the immediate post-transplant period in patients who have undergone their first liver transplant.

Conditions

  • de Novo Liver Transplantation

Interventions

DRUG

AEB071

Sponsors & Collaborators

Principal Investigators

  • Novartis · Investigator site

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-02-28

Countries

  • Germany
  • Italy
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00545259 on ClinicalTrials.gov